Fisher Funds Management LTD Buys Shares of 10,734 Solventum Co. (NYSE:SOLV)

Fisher Funds Management LTD purchased a new position in shares of Solventum Co. (NYSE:SOLV) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 10,734 shares of the company’s stock, valued at approximately $709,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Trian Fund Management L.P. grew its holdings in Solventum by 32.9% during the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after acquiring an additional 1,765,676 shares during the period. State Street Corp boosted its position in shares of Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Solventum by 4.0% during the third quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock worth $232,608,000 after purchasing an additional 128,317 shares during the period. Hotchkis & Wiley Capital Management LLC bought a new stake in Solventum in the third quarter valued at about $125,488,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Solventum by 0.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock valued at $73,469,000 after buying an additional 3,745 shares during the period.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on SOLV shares. Mizuho assumed coverage on Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price for the company. Morgan Stanley boosted their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Finally, Piper Sandler upped their target price on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $68.29.

Solventum Trading Down 1.9 %

Shares of SOLV opened at $73.08 on Monday. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The firm’s 50 day moving average price is $71.14 and its two-hundred day moving average price is $69.24.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.